

XCYTE THERAPIES INC  
Form 8-K  
May 13, 2004

---

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of  
the Securities Act of 1934

Date of Report (Date of earliest event reported): May 13, 2004

Commission File Number 0-50626

---

**XCYTE THERAPIES, INC.**

(Exact name of registrant as specified in its charter)

---

Delaware  
(State or other jurisdiction of  
incorporation or organization)

91-1707622  
(I.R.S. Employer  
Identification Number)

1124 Columbia Street, Suite 130

Edgar Filing: XCYTE THERAPIES INC - Form 8-K

Seattle, Washington 98104

(Address of principal executive offices and zip code)

(206) 262-6200

(Registrant's telephone number, including area code)

---

**Item 7. Financial Statements and Exhibits**

(c) Exhibits

99.1 Press Release of Xcyte Therapies, Inc. dated May 13, 2004.

**Item 12. Results of Operations and Financial Condition**

On May 13, 2004, Xcyte Therapies, Inc. issued a press release announcing financial results for its first quarter ended March 31, 2004. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated into this Form 8-K by reference.

The information in this Form 8-K, including the attached Exhibit, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

XCYTE THERAPIES, INC.

By: /s/ Kathi L. Cordova

---

Kathi L. Cordova

*Duly Authorized Officer of Registrant and Principal  
Financial Officer*

*Senior Vice President of Finance and  
Treasurer*

Date: May 13, 2004

INDEX TO EXHIBITS

<u>Exhibit Number</u>	<u>Description of Document</u>
99.1	Press Release of Xcyte Therapies, Inc. dated May 13, 2004.